Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 16/20 | 0.74 |
| ▸ | PDE4A | P27815 | 13/20 | 0.74 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.74 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.74 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.53 |
| ▸ | PDE5A | O76074 | 2/20 | 0.53 |
| ▸ | PDE1A | P54750 | 1/20 | 0.53 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.53 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7450501 | 0.91 | PDE4D (0.75) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL7512973 | 0.90 | PDE4D (0.74) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL201172 | 0.85 | PDE4D (0.84) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL7450727 | 0.85 | PDE4D (1.00) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL201574 | 0.83 | PDE4D (0.74) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL8323597 | 0.82 | PDE4A (0.66) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL7424626 | 0.82 | PDE4A (0.66) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL7424332 | 0.78 | PDE4D (0.60) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL7458162 | 0.77 | PDE4D (1.00) | PDE4DPDE4APDE4BPDE4CEPHX2 | |
| SCHEMBL7422814 | 0.75 | PDE4A (0.59) | PDE4DPDE4APDE4BPDE4CEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088804-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088804-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088804-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2338878-A2 | N-hydroxyamide derivatives possessing antibacterial activity | Vicuron Pharmaceuticals, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| EP-2193808-A1 | Synergistic combination | Nycomed GmbH (DE) | 2010-06-09 | — | — | EP | disclosed |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. | 2010-01-28 | — | — | US | disclosed |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. | 2010-01-28 | — | — | US | disclosed |
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. | 2010-01-28 | — | — | US | disclosed |
| EP-1849468-A2 | Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist | Nycomed GmbH (DE) | 2007-10-31 | — | — | EP | disclosed |
| WO-2003024488-A2 | COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022605-A1 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | NAAA, HDHD5, HACL2 | PDE4D 1900/4885PDE4A 2034/4885PDE4B 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.